A prospective randomized controlled study on the effects of IFN therapy against hepatocarcinogenesis found that in patients with HCV-related compensated cirrhosis, IFN therapy significantly improved liver function and decreased the incidence of HCC (4% in IFN-treated patients versus 17% in untreated patients) [18]. Here, IFNA1 is linked to Cirrhosis.